October 16th, 2020 | 12:19 CEST
CureVac, BioNTech, Valeo Pharma: Where is there still potential?
The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac recently started its phase study IIa in Peru and Panama. Around 700 people are taking part in it. The study aims to find suitable dosages for the vaccine. To this end, test persons are vaccinated twice within 28 days. Other competitors, such as BioNTech, are already testing their vaccine on more volunteers. BioNTech recently started its phase III study in South Africa and is testing the vaccine on more than 40,000 people worldwide.
time to read: 2 minutes
|
Author:
Nico Popp
ISIN:
CA91915B1085 , US09075V1026 , NL0015436031
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Nico Popp
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Tag cloud
Shares cloud
CureVac and BioNTech: There will be losers
That the race for a vaccine is fierce is also shown by the share prices. All vaccine shares received advanced praise in the first half of the year, and some shares rose significantly. However, CureVac has been running into sand for a few days now - the stock lost around 4% within five days. Although the share price development is of little relevance, as the Company only went public during the pandemic and is therefore ambitiously valued, there are increasing signs of weakness.
The BioNTech share has not got off the ground lately. This performance may be bearable given the 540% increase in value within one year, but investors are rightly asking themselves how things will continue with vaccination shares. The foreign competition seems to have managed - also thanks to laxer approval procedures - to overtake German companies. According to Russia, it has already developed a second vaccine. The Chinese supplier Sinopharm now offers students an experimental vaccine free of charge. Almost 500,000 test persons have already been vaccinated. The measures aim to increase confidence in the vaccine.
There will be several vaccines in the future, and the preparations from Russia and China, which are being fast-tracked, will not render competition for established biotech companies in Europe and the USA. There will also be losers in the race for the best vaccines, especially for stocks like CureVac and also BioNTech, as the drop could be from a high level. For investors, it may make sense to step out of the race for the vaccine and think about alternatives.
A healthy immune system not only helps with Covid-19
The pandemic proves that a functioning immune system can not only make the difference between life and death in the worst-case scenario but also helps to ward off diseases completely. The Canadian Company Valeo Pharma is focused on the commercialization of Hesperco™, a dietary supplement containing a highly effective antioxidant intended to support the immune system. It was approved by the Canadian authorities a few weeks ago, and three days ago, Valeo Pharma announced that it had begun shipping the product. The capsules will be available at all major retailers in Canada in early November.
Valeo Pharma is at the beginning of its investment story
Valeo Pharma is working with Ingenew Pharma in the development, production, and distribution of the new dietary supplement, which provides all the necessary scientific data on the new product. In addition to Hesperco™, Valeo Pharma offers prescription drugs and focuses on neurodegenerative diseases, oncological products, and special hospital needs. Although Valeo Pharma's share price has also recently had to give up its feathers, the Company is still at the beginning of its investment story. The small Canadian Company has not yet received any advance praise from the market, such as CureVac or BioNTech. Nevertheless, the stock could benefit indirectly from the pandemic.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
